Trial Profile
A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 May 2013
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 06 Nov 2009 Results were presented at the Ninth Annual Diabetes Technology Meeting, accoridng to an Intarcia media release.
- 30 Sep 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
- 30 Sep 2009 Final results presented at EASD 2009, according to an Intarcia Therapeutics media release.